

Jianfeng Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3781270/publications.pdf>

Version: 2024-02-01

46
papers

2,437
citations

159585

30
h-index

223800

46
g-index

47
all docs

47
docs citations

47
times ranked

3071
citing authors

#	ARTICLE	IF	CITATIONS
1	Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma. <i>ACS Nano</i> , 2020, 14, 4816-4828.	14.6	205
2	Gold nanoparticles enlighten the future of cancer theranostics. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 6131-6152.	6.7	202
3	Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. <i>ACS Nano</i> , 2020, 14, 5075-5089.	14.6	144
4	Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. <i>Biomaterials</i> , 2012, 33, 7775-7784.	11.4	115
5	Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?. <i>Biotechnology Advances</i> , 2011, 29, 402-417.	11.7	98
6	The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics. <i>Biomaterials</i> , 2015, 66, 53-66.	11.4	90
7	Pharmacokinetic, pharmacodynamic and biodistribution following oral administration of nanocarriers containing peptide and protein drugs. <i>Advanced Drug Delivery Reviews</i> , 2016, 106, 367-380.	13.7	83
8	Systemic delivery of therapeutic small interfering RNA using a pH-triggered amphiphilic poly-l-lysine nanocarrier to suppress prostate cancer growth in mice. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 45, 521-532.	4.0	79
9	Mechanistic studies on the uptake and intracellular trafficking of novel cyclodextrin transfection complexes by intestinal epithelial cells. <i>International Journal of Pharmaceutics</i> , 2011, 413, 174-183.	5.2	73
10	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. <i>Theranostics</i> , 2020, 10, 3099-3117.	10.0	70
11	Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. <i>Molecular Cancer</i> , 2021, 20, 10.	19.2	70
12	Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells. <i>International Journal of Pharmaceutics</i> , 2016, 509, 16-27.	5.2	68
13	A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 378-393.	12.0	63
14	Tackling TAMs for Cancer Immunotherapy: It's Nano Time. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 701-714.	8.7	60
15	Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, <i>in Vitro</i> Mechanistic Studies, and <i>in Vivo</i> Patient Derived Therapeutic Efficacy. <i>Molecular Pharmaceutics</i> , 2017, 14, 940-952.	4.6	56
16	Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. <i>Molecular BioSystems</i> , 2010, 6, 1143-61.	2.9	53
17	Membrane-core nanoparticles for cancer nanomedicine. <i>Advanced Drug Delivery Reviews</i> , 2020, 156, 23-39.	13.7	53
18	Folate-targeted amphiphilic cyclodextrin.siRNA nanoparticles for prostate cancer therapy exhibit PSMA mediated uptake, therapeutic gene silencing <i>in vitro</i> and prolonged circulation <i>in vivo</i> . <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 2341-2351.	3.3	48

#	ARTICLE	IF	CITATIONS
19	A Low Molecular Weight Hyaluronic Acid Derivative Accelerates Excisional Wound Healing by Modulating Pro-Inflammation, Promoting Epithelialization and Neovascularization, and Remodeling Collagen. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3722.	4.1	46
20	Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer – synthesis, physicochemical characterisation and in vitro evaluation. <i>Journal of Materials Chemistry B</i> , 2016, 4, 2242-2252.	5.8	45
21	The role of transcription factors in prostate cancer and potential for future RNA interference therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 633-649.	3.4	44
22	Formulation and Evaluation of Anisamide-Targeted Amphiphilic Cyclodextrin Nanoparticles To Promote Therapeutic Gene Silencing in a 3D Prostate Cancer Bone Metastases Model. <i>Molecular Pharmaceutics</i> , 2017, 14, 42-52.	4.6	44
23	Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 137, 56-67.	4.3	43
24	Role of Hyaluronic Acids and Potential as Regenerative Biomaterials in Wound Healing. <i>ACS Applied Bio Materials</i> , 2021, 4, 311-324.	4.6	40
25	Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, 9.	9.1	40
26	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. <i>Biotechnology Advances</i> , 2014, 32, 1396-1409.	11.7	38
27	Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer?. <i>Trends in Molecular Medicine</i> , 2013, 19, 250-261.	6.7	36
28	Evaluation of the physicochemical properties and the biocompatibility of polyethylene glycol-conjugated gold nanoparticles: A formulation strategy for siRNA delivery. <i>Colloids and Surfaces B: Biointerfaces</i> , 2015, 135, 604-612.	5.0	36
29	Targeted Drug Delivery via Folate Receptors for the Treatment of Brain Cancer: Can the Promise Deliver?. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 3413-3420.	3.3	36
30	Nano co-delivery of Plumbagin and Dihydrotanshinone I reverses immunosuppressive TME of liver cancer. <i>Journal of Controlled Release</i> , 2022, 348, 250-263.	9.9	36
31	Modulation of macrophages by a paeoniflorin-loaded hyaluronic acid-based hydrogel promotes diabetic wound healing. <i>Materials Today Bio</i> , 2021, 12, 100139.	5.5	32
32	Nanoparticle-mediated siRNA delivery assessed in a 3D co-culture model simulating prostate cancer bone metastasis. <i>International Journal of Pharmaceutics</i> , 2016, 511, 1058-1069.	5.2	30
33	Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells. <i>Methods in Molecular Biology</i> , 2019, 1974, 291-301.	0.9	30
34	Amphiphilic polyallylamine based polymeric micelles for siRNA delivery to the gastrointestinal tract: In vitro investigations. <i>International Journal of Pharmaceutics</i> , 2013, 447, 150-157.	5.2	28
35	Positively charged, surfactant-free gold nanoparticles for nucleic acid delivery. <i>RSC Advances</i> , 2015, 5, 17862-17871.	3.6	28
36	Development of anisamide-targeted PEGylated gold nanorods to deliver epirubicin for chemo-photothermal therapy in tumor-bearing mice. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1817-1833.	6.7	26

#	ARTICLE	IF	CITATIONS
37	Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy. <i>Drug Discovery Today</i> , 2021, 26, 651-662.	6.4	23
38	A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer. <i>International Journal of Pharmaceutics</i> , 2021, 606, 120888.	5.2	23
39	Biomimetic gold nanocomplexes for gene knockdown: Will gold deliver dividends for small interfering RNA nanomedicines?. <i>Nano Research</i> , 2015, 8, 3111-3140.	10.4	22
40	The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. <i>Journal of Controlled Release</i> , 2018, 286, 154-166.	9.9	19
41	7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice. <i>Investigational New Drugs</i> , 2016, 34, 15-23.	2.6	18
42	RNA interference for multiple myeloma therapy: targeting signal transduction pathways. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 107-121.	3.4	16
43	Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy. <i>Nature Protocols</i> , 2022, 17, 1818-1831.	12.0	10
44	Targeting epigenetic modifiers to reprogramme macrophages in non-resolving inflammation-driven atherosclerosis. <i>European Heart Journal Open</i> , 2021, 1, .	2.3	9
45	A chlorogenic acid-loaded hyaluronic acid-based hydrogel facilitates anti-inflammatory and pro-healing effects for diabetic wounds. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 70, 103232.	3.0	5
46	The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma. <i>Pharmaceutical Nanotechnology</i> , 2019, 6, 221-231.	1.5	4